Product Information

DABIGATRAN ETEXILATE 150 MG CP is a generic product labeled by Apotex Corp., priced at $0.8226 per EA under NDC 60505434806. Its NADAC has been published 125 times since Apr 3, 2024.

FDA first approved this application on Dec 15, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

DABIGATRAN ETEXILATE 150 MG CP

dabigatran etexilate
$0.8226per EA

Strength

150 mg/1

Manufacturer

Apotex Corp.

NDC

60505434806

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

8/19/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA208070

FDA Approved

12/15/2023

TE Code

AB

On Market Since

2/13/2024

Pharmacological Classes

Direct Thrombin Inhibitor
Thrombin Inhibitors

Price Statistics

The NADAC for DABIGATRAN ETEXILATE 150 MG CP has been published 125 times since Apr 3, 2024, and over the history we have for it it has declined 70.8%. The table below summarizes its recorded NADAC range and movement.

Current price$0.8226 per EA
All-time high$2.8528 (Jul 10, 2024)
All-time low$0.8226 (Aug 19, 2026)
52-week high$1.2631
52-week low$0.8226
Median price$1.4935
Average price$1.5290
Largest weekly change+47.0% (Jun 19, 2024)
Weeks tracked125
Tracking sinceApr 3, 2024

Price History

1W

-3.5%

1M

-3.5%

3M

-5.0%

6M

-2.6%

1Y

-34.9%

3Y

N/A

5Y

N/A

All

-70.8%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the dabigatran etexilate market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of DABIGATRAN ETEXILATE 150 MG CP?

The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 150 MG CP, manufactured by Apotex Corp., is $0.8226 per EA (NDC 60505434806), effective Aug 19, 2026.

How has the price of DABIGATRAN ETEXILATE 150 MG CP changed over time?

Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has declined 70.8%. It has been tracked across 125 weekly CMS publications since Apr 3, 2024.

What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 150 MG CP?

Since Apr 3, 2024, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has ranged from a low of $0.8226 (Aug 19, 2026) to a high of $2.8528 (Jul 10, 2024), with a median of $1.4935 per EA.

Are there cheaper alternatives to DABIGATRAN ETEXILATE 150 MG CP?

No other NADAC-published product currently shares the active ingredient and strength of DABIGATRAN ETEXILATE 150 MG CP in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures DABIGATRAN ETEXILATE 150 MG CP?

DABIGATRAN ETEXILATE 150 MG CP (NDC 60505434806) is labeled by Apotex Corp., and CMS classifies it as a generic product.